A Single-Arm,Multicenter Phase, Phase II Clinical Trial of Adebrelimab Combined With Trametinib in the Treatment of Refractory Recurrent Langerhans Cell Histiocytosis in Children and Adolescents

Based on clinical observation data from two previously enrolled cases, the adezbelimab combined with trametinib regimen showed good safety in pediatric refractory relapsed LCH, with good drug tolerance. Both children benefited clinically from the combination regimen, preliminarily validating the feasibility and effectiveness of this regimen in treating refractory relapsed LCH in children. To systematically validate the clinical efficacy and safety of this combination regimen in treating refractory relapsed LCH, expand the sample size, and improve evidence-based medical evidence, this study plans to conduct a prospective single-arm, multicenter Phase II clinical trial of adebrelimab combined with trametinib for refractory Langerhans cell histiocytosis, aiming to optimize treatment regimens for children with refractory relapsed LCH and further improve clinical survival rates and long-term quality of life.